Literature DB >> 25429314

Management of "very early" hepatocellular carcinoma on cirrhotic patients.

Gonzalo Sapisochin1, Elena Fernandez de Sevilla1, Juan Echeverri1, Ramón Charco1.   

Abstract

Due to the advances in screening of cirrhotic patients, hepatocellular carcinoma (HCC) is being diagnosed in earlier stages. For this reason the number of patients diagnosed of very early HCC (single tumors ≤ 2 cm) is continuously increasing. Once a patient has been diagnosed with this condition, treatment strategies include liver resection, local therapies or liver transplantation. The decision on which therapy should the patient undergo depends on the general patients performance status and liver disease. Anyway, even in patients with similar conditions, the best treatment offer is debatable. In this review we analyze the state of the art on the management of very early HCC on cirrhotic patients to address the best treatment strategy for this patient population.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver resection; Liver transplantation; Local therapies; Very early

Year:  2014        PMID: 25429314      PMCID: PMC4243150          DOI: 10.4254/wjh.v6.i11.766

Source DB:  PubMed          Journal:  World J Hepatol


  104 in total

Review 1.  Liver resection and transplantation in hepatocellular carcinoma.

Authors:  J Belghiti; D Fuks
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

2.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

3.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

6.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

Review 7.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

Review 8.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

9.  Predictors and patterns of recurrence after resection of hepatocellular carcinoma.

Authors:  Charles Cha; Yuman Fong; William R Jarnagin; Leslie H Blumgart; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  9 in total

Review 1.  Liver transplantation for cholangiocarcinoma: Current status and new insights.

Authors:  Gonzalo Sapisochín; Elena Fernández de Sevilla; Juan Echeverri; Ramón Charco
Journal:  World J Hepatol       Date:  2015-10-08

Review 2.  Cholangiocarcinoma.

Authors:  Paul J Brindley; Melinda Bachini; Sumera I Ilyas; Shahid A Khan; Alex Loukas; Alphonse E Sirica; Bin Tean Teh; Sopit Wongkham; Gregory J Gores
Journal:  Nat Rev Dis Primers       Date:  2021-09-09       Impact factor: 65.038

3.  MicroRNA-9 is a ponderable index for the prognosis of human hepatocellular carcinoma.

Authors:  Jingchang Sun; Kunpeng Fang; Hang Shen; Yeben Qian
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Hepatitis B virus promotes cancer cell migration by downregulating miR-340-5p expression to induce STAT3 overexpression.

Authors:  Qiushuang Xiong; Shaoshuai Wu; Jingwen Wang; Xianhuang Zeng; Jianwen Chen; Mingcong Wei; Haotong Guan; Chengpeng Fan; Lang Chen; Deyin Guo; Guihong Sun
Journal:  Cell Biosci       Date:  2017-04-12       Impact factor: 7.133

Review 5.  Liver transplantation for intrahepatic and hilar cholangiocellular carcinoma: Most recent updates in the literature.

Authors:  Susumu Eguchi; Masaaki Hidaka; Takanobu Hara; Hajime Matsushima; Akihiko Soyama
Journal:  Ann Gastroenterol Surg       Date:  2022-03-23

6.  MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma.

Authors:  Chen-Dan Zou; Wei-Ming Zhao; Xiao-Na Wang; Qiang Li; Hui Huang; Wan-Peng Cheng; Jian-Feng Jin; He Zhang; Ming-Juan Wu; Sheng Tai; Chao-Xia Zou; Xu Gao
Journal:  Oncotarget       Date:  2016-01-05

7.  MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.

Authors:  Fei Xue; Yuntian Liang; Zhenrong Li; Yanhui Liu; Hongwei Zhang; Yu Wen; Lei Yan; Qiang Tang; Erhui Xiao; Dongyi Zhang
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

8.  Treatment of solitary hepatocellular carcinoma up to 2 cm: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Hongyan Fan; Chenggang Zhou; Jianzhou Yan; Weihua Meng; Wenquan Zhang
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

9.  Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian Patients

Authors:  Aya H Mashaly; Rokiah Anwar; Mohamed A Ebrahim; Laila A Eissa; Mamdouh M El Shishtawy
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.